UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (102) 102
life sciences & biomedicine (96) 96
humans (69) 69
oncology (56) 56
carcinoma, renal cell - drug therapy (44) 44
male (44) 44
female (42) 42
kidney neoplasms - drug therapy (41) 41
urology & nephrology (41) 41
middle aged (37) 37
metastasis (35) 35
carcinoma, renal cell (34) 34
kidney neoplasms - pathology (31) 31
aged (30) 30
renal cell carcinoma (30) 30
treatment outcome (28) 28
care and treatment (27) 27
antineoplastic agents - therapeutic use (23) 23
cancer (23) 23
carcinoma, renal cell - mortality (23) 23
prognosis (23) 23
retrospective studies (23) 23
kidney neoplasms - mortality (22) 22
urology (22) 22
carcinoma, renal cell - secondary (21) 21
targeted therapy (20) 20
hematology, oncology and palliative medicine (19) 19
disease-free survival (18) 18
neoplasm metastasis (17) 17
vascular endothelial growth factor (17) 17
adult (16) 16
aged, 80 and over (16) 16
patient outcomes (16) 16
analysis (15) 15
carcinoma, renal cell - pathology (15) 15
immunotherapy (14) 14
vascular endothelial growth factor a - antagonists & inhibitors (14) 14
databases, factual (13) 13
indoles - therapeutic use (13) 13
kidney cancer (13) 13
molecular targeted therapy (13) 13
pyrroles - therapeutic use (13) 13
risk factors (13) 13
abridged index medicus (12) 12
kaplan-meier estimate (12) 12
antineoplastic agents (11) 11
metastatic renal cell carcinoma (11) 11
research (11) 11
survival analysis (11) 11
survival rate (11) 11
time factors (10) 10
antimitotic agents (9) 9
bevacizumab (9) 9
molecular targeted therapy - methods (9) 9
niacinamide - analogs & derivatives (9) 9
sunitinib (9) 9
proportional hazards models (8) 8
protein kinase inhibitors - therapeutic use (8) 8
pyridines - therapeutic use (8) 8
biomarkers (7) 7
metastases (7) 7
prognostic factors (7) 7
sirolimus - analogs & derivatives (7) 7
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
canada (6) 6
carcinoma (6) 6
carcinoma, renal cell - metabolism (6) 6
clear cell-type renal cell carcinoma (6) 6
follow-up studies (6) 6
kidney neoplasms (6) 6
kidney neoplasms - metabolism (6) 6
nephrectomy (6) 6
overall survival (6) 6
sirolimus - therapeutic use (6) 6
tor serine-threonine kinases - antagonists & inhibitors (6) 6
angiogenesis inhibitors - therapeutic use (5) 5
antibodies, monoclonal - therapeutic use (5) 5
carcinoma, renal cell - genetics (5) 5
chemotherapy (5) 5
clinical trials (5) 5
drug therapy (5) 5
health aspects (5) 5
hospitals (5) 5
international metastatic renal cell carcinoma database consortium (5) 5
medical colleges (5) 5
medical prognosis (5) 5
neoplasm staging (5) 5
randomized controlled trials as topic (5) 5
risk assessment (5) 5
studies (5) 5
survival (5) 5
toxicity (5) 5
anilides - therapeutic use (4) 4
antibodies, monoclonal, humanized (4) 4
antineoplastic agents - administration & dosage (4) 4
benzenesulfonates - therapeutic use (4) 4
cabozantinib (4) 4
carcinoma, renal cell - surgery (4) 4
carcinoma, renal cell - therapy (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European urology, ISSN 0302-2838, 2014, Volume 66, Issue 3, pp. 502 - 509
Abstract Background Bone metastases (BMs) are frequently present in patients with metastatic renal cell carcinoma (mRCC) and cause significant morbidity.... 
Urology | mTOR inhibitors | VEGF-targeted therapy | Renal cell carcinoma | Bisphosphonates | Bone metastases | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Niacinamide - analogs & derivatives | Prognosis | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | Hypocalcemia - chemically induced | Renal Insufficiency - chemically induced | Diphosphonates - therapeutic use | Female | Retrospective Studies | Bone Neoplasms - drug therapy | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Diphosphonates - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Bone Density Conservation Agents - adverse effects | Interferon-alpha - therapeutic use | Bone Density Conservation Agents - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Survival Rate | Disease-Free Survival | Carcinoma, Renal Cell - secondary | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Care and treatment | Metastasis | Carcinoma, Renal cell | Index Medicus | VEGF targeted therapy
Journal Article
Journal Article
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 07/2016, Volume 17, Issue 7, pp. 917 - 927
Journal Article
Breast cancer research and treatment, ISSN 1573-7217, 12/2013, Volume 143, Issue 3, pp. 459 - 467
Journal Article
European urology, ISSN 0302-2838, 2014, Volume 67, Issue 3, pp. 441 - 447
Abstract Background Although abiraterone acetate (abiraterone) has proven efficacy in two randomised phase 3 trials in metastatic castration-resistant prostate... 
Urology | Castration-resistant prostate cancer | Prostate cancer | Abiraterone acetate | ECOG | Performance status | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Multivariate Analysis | Cytochrome P-450 Enzyme Inhibitors - therapeutic use | Humans | Middle Aged | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Kallikreins - blood | Retrospective Studies | Prostatic Neoplasms, Castration-Resistant - blood | Steroid Synthesis Inhibitors - adverse effects | Risk Factors | Abiraterone Acetate - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Steroid Synthesis Inhibitors - therapeutic use | Logistic Models | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostate-Specific Antigen - blood | Canada | Neoplasms, Hormone-Dependent - blood | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Neoplasms, Hormone-Dependent - drug therapy | Health Status | Care and treatment | Cancer patients | Metastasis | Acetates | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article